Intravenous sustained-release nifedipine ameliorates nonalcoholic fatty liver disease by restoring autophagic clearance

Obesity and overweight, the most serious health problems, are associated with chronic metabolic complications such as type 2 diabetes, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). However, current pharmacological therapies for obesity are challenged by potential side effects, lo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomaterials 2019-03, Vol.197, p.1-11
Hauptverfasser:	Lee, Solji, Han, Daewon, Kang, Hyun-Goo, Jeong, Su Jin, Jo, Jae-Eun, Shin, Jongdae, Kim, Do Kyung, Park, Hwan-Woo
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Animals Autophagy - drug effects Calcium channel blocker Calcium Channel Blockers - administration & dosage Calcium Channel Blockers - therapeutic use Delayed-Action Preparations - chemistry Endoplasmic Reticulum Stress - drug effects Hep G2 Cells Humans Insulin Resistance Male Mice, Inbred C57BL Nifedipine Nifedipine - administration & dosage Nifedipine - therapeutic use Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - metabolism Nonalcoholic fatty liver disease Obesity - drug therapy Obesity - metabolism PLGA nanoparticle Polylactic Acid-Polyglycolic Acid Copolymer - chemistry Protein inclusion
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!